Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
- Subjects either with a histological confirmed diagnosis of cancer or a history of previous cancer specific treatment destined to initiate hormonal and/or chemotherapy treatments. This includes cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician or after failure of therapy.
- Subjects with a histological confirmed diagnosis of cancer who are destined to initiate standard of care therapeutic interventions.This includes cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician.
- Subjects with non-localized cancer being followed or treated at Mayo Clinic as part of standard clinical care.
- Non-cancer subjects age Birth to 100 years; Subject must be able to sign an informed consent or if subject is under the age of 18 have a legal guardian who can read, make an informed decision and sign on behalf of the minor . Informed consent must be signed at the time of enrollment and/or collection of any specimen and/or clinical data (other than PHI needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study).
- To collect samples from 4 generations of family(s), persons under the age of 18 will be asked to participate in this study.
- Subjects and/or guardians either incarceratedor with limited decision making capacity
- Subjects clinically judged to be at increased risk of bleeding from phlebotomy
- Subjects with hemoglobin